According to a recent news release, researchers at Columbia University Medical Center have recently identified immune cells responsible for destroying hair follicles. After investigators found that ruxolitinib, restored hair in mice that experienced extensive hair loss from alopecia areata, researchers initiated a small, open-label clinical trial of the drug in humans. Ruxolitinib, which is FDA approved for the treatment of myelofibrosis, demonstrated complete hair regrowth in three patients within four to five months after starting the treatment. “We still need to do more testing to establish that ruxolitinib should be used in alopecia areata, but this is exciting news for patients,” said Raphael Clynes, M.D., Ph.D., a cellular immunologist at Columbia University Medical Center and head of the research team.
September 10, 2014
Tags: alopecia areata